Acute Myeloid Leukemia

Data: Clofarabine achieves high response rates in AML

Published in Cancer Weekly, January 4th, 2005

Bioenvision, Inc., (BIVN) announced that results presented at the 46th American Society of Hematology meeting showed that clofarabine achieved a 3-fold greater overall response rate than current best standard of care in older patients with acute myeloid leukemia (AML) who were unsuitable for intensive chemotherapy.

In a European multicenter study, clofarabine was administered first line, as a monotherapy, to 30 patients over 60 years of age with AML and 13 (43%) patients achieved a complete response (CR); 4 (13%) patients achieved a complete response without full platelet recovery; and 3 (10%) achieved a partial remission, thus giving an overall response rate of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-01-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry